Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Christina Cheddar"


25 mentions found


Revenue from obesity treatment Zepbound is forecast to climb to $1.73 billion from $1.24 billion quarter over quarter. For the year, analysts expect Mounjaro sales to reach $4.58 billion, while Zepbound revenue is seen rising to $5.88 billion. The consensus view for combined sales of both drugs now stands at $30.19 billion, according to FactSet. Other key announcements A clinical trial is in progress that pits Zepbound against Novo Nordisk's Wegovy in obesity treatment. Beyond obesity, Lilly has begun treating patients with Kisunla, its Alzheimer's disease treatment.
Persons: Eli Lilly, Lilly, Seamus Fernandez, Morgan Stanley, Terence Flynn, David Risinger, Morgan Stanley's Flynn, Mounjaro, Cantor, Louise Chen, , Fred Imbert Organizations: Investment, Food, Leerink, Novo Nordisk's, FDA, Kisunla Locations: U.S
Dexcom — Shares slid nearly 7%, despite the manufacturer of diabetes management devices posting a third-quarter adjusted earnings and revenue beat. L3Harris reported adjusted earnings of $3.34 per share on revenue of $5.29 billion, while analysts polled by LSEG had expected $3.26 per share on $5.28 billion in revenue. Boyd reported adjusted earnings of $1.52 a share, beating the consensus estimate of analysts polled by FactSet by 12 cents. In the third quarter, Capital One reported adjusted earnings of $4.51 per share on revenue of $10.01 billion. The company's provision for credit losses came in at $2.48 billion, versus the $2.83 billion estimate from analysts polled by StreetAccount.
Persons: Dexcom, LSEG, Kate Spade, Gucci, Michael Kors, Jimmy Choo, FactSet, Morgan Stanley, Skechers, Boyd, Darla Mercado, Lisa Kailai Han, Christina Cheddar Berk Organizations: Technologies, Tapestry, LSEG, Kinsale Capital, Kinsale, Joby Aviation, Allen, Co, FactSet, Boyd, Revenue, StreetAccount Locations: Kinsale
Abercrombie & Fitch - Shares of the teen apparel retailer jumped nearly 8% after JPMorgan added it to its positive catalyst watch list. JetBlue shares jumped more than 15% on the news. Summit Therapeutics – The biopharmaceutical company added 2%. Other international shipping stocks saw losses as well, including Danish shipping giant Maersk at 5% . CVS Health — The company's shares added 3.3%.
Persons: Abercrombie &, Matthew Boss, Hollister, Tencent, — CNBC's Sean Conlon, Hakyung Kim, Christina Cheddar, Berk, Lisa Kailai Han Organizations: Abercrombie, Abercrombie & Fitch, JPMorgan, Spirit Airlines, JetBlue Airways —, Wall Street, JetBlue, Vistra, Nvidia, Therapeutics, Drug Administration, Ubisoft Entertainment, Bloomberg News, Ubisoft, SilverCrest Metals, Mining, Zim Integrated Shipping Services —, U.S, dockworkers, United States Maritime Alliance, Maersk, CVS Health, CNBC, CVS
AI drug pioneer Recursion Pharmaceuticals said Wednesday that one of its experimental treatments hit a key milestone. The Food and Drug Administration cleared the investigational new drug application for a phase 1/2 clinical trial of an experimental drug candidate known as REC-1245. The company said the potential market for this treatment could be more than 100,000 patients in the U.S. and European Union. The trial will evaluate the safety and tolerability of REC-1245 and will begin in the fourth quarter of this year. "It's the first program that really is leveraging many of these new tools that we've built in one unit."
Persons: Chris Gibson, Gibson Organizations: Pharmaceuticals, CNBC, Drug Administration, Union, REC Locations: U.S
Lilly's shares are up more than 7% on the news. LLY YTD mountain Eli Lilly shares year to date. The first followed positive reports from rivals that showed they were making progress in developing their own weight loss drugs . However, sales rose 59% for Mounjaro quarter over quarter and were up 140% for Zepbound as Lilly saw better pricing. Meanwhile, analysts see several events on the horizon that could further boost Lilly's shares in coming months.
Persons: Eli Lilly, Bansal, Lilly, Carter Gould, Lilly's headwinds, Novo's, Wells Fargo's Bansal, Evan David Seigerman, Chris Schott, Schott, Lilly's Organizations: Novo Nordisk, Wells, Barclays, Nordisk, BMO Capital Markets, Food and Drug Administration Locations: Wells Fargo, Lilly's, Wednesday's
Novo Nordisk shocked investors on Wednesday when its latest results fell short of Wall Street's expectations. While Eli Lilly's stock remains up about 32% year to date, concerns about increasing competition in the category have resulted in a nearly 16% decline for Lilly shares over the past month. Eli Lilly is making similar attempts with Zepbound, but its launch is at an earlier stage than Wegovy. Second-quarter sales of Ozempic, Novo's diabetes treatment, rose 4% from the first quarter, while Wegovy revenue grew 24% quarter over quarter. Barclays analyst Emily Field told clients in a research note that she would be a buyer of Novo Nordisk shares on the weakness.
Persons: Eli Lilly, Eli, Lilly, Wells, Mohit Bansal, Ozempic, Bansal, Emily Field, David Song, Song, Chris Schott, Schott Organizations: Novo Nordisk, LSEG, Lilly's, Management, Food and Drug Administration, Barclays, Tema, JPMorgan Locations: Wells Fargo, IQVIA, Amgen, MariTide, Novo, CagriSema
With billions at stake, that's pretty much been a guarantee facing the current market leaders, Eli Lilly and Novo Nordisk , from the start. Their updates are likely to be joined by others in the coming months even as today's incumbents develop their own next-generation weight loss treatments. Other analysts have also grown more optimistic about the future of weight loss treatments. Orforglipron, a once-a-day oral GLP-1 drug that Lilly is working on, had shown a 3% weight loss at 4 weeks. The company is also exploring whether the weight loss treatment could be given only once a month.
Persons: Eli Lilly, drugmakers Roche, Lilly, Denmark's, Trung Huynh, Huynh, Rajesh Kumar, Kumar, Novo, Roche, Roche ADRs, Justin Zelin, Zelin, Viking's, HSBC's Kumar, Novo aren't, , Nick Wells Organizations: Novo Nordisk, Viking Therapeutics, UBS, HSBC Global Research, Carmot Therapeutics, Food and Drug Administration, Viking, European Association for, Diabetes, Pfizer, Amgen, Therapeutics Locations: Swiss, Novo, San Antonio, Spain
Southwest reported 58 cents in adjusted earnings per share on $7.35 billion of revenue. Analysts surveyed by LSEG were looking for a profit of 51 cents per share on $7.32 billion in revenue. RTX reported $1.41 earnings per share, ex-items, compared to analysts' estimate of $1.30 per share, according to LSEG. KLA reported adjusted earnings of $6.60 per share, higher than analysts' expectations of $6.15 per share, according to LSEG. Ford reported adjusted earnings per share of 47 cents, significantly less than the consensus forecast of 68 cents, per LSEG.
Persons: oversupply, overshadowing, AbbVie, Dow, LSEG, Northrop Grumman, Dr Pepper, ServiceNow, CJ Desai, Molina, FactSet, Edwards, Ford, , Yun Li, Jesse Pound, Christina Cheddar Berk, Fred Imbert Organizations: Airlines —, American Airlines, Honeywell —, Southwest Airlines —, Hasbro, IBM, Northrop, LSEG, Nasdaq, KLA Corporation, U.S . Army, Molina Healthcare, Technology, Ford, Viking Therapeutics Locations: LSEG
Tesla reported adjusted earnings per share at 52 cents, while analysts surveyed by LSEG had called for 62 cents per share. Visa reported $8.9 billion in revenue, which came in slightly below the $8.92 billion forecast by analysts polled by LSEG. Its adjusted earnings per share of 19 cents topped analysts' estimates for 17 cents per share, according to LSEG data. In the fiscal fourth quarter, earnings of $2.32 per share were higher than a year ago, but shy of the $2.41 per share analysts predicted, according to FactSet. Revenue of $304 million also fell short of the $310 million analysts forecast.
Persons: Tesla, LSEG, Enphase, Chubb, , Christina Cheddar Berk Organizations: Street, Visa, LSEG, Seagate —, Seagate, Capital, Revenue, Texas, Mattel, Maine, Enphase Energy Locations: Santa Monica , California, Cal, LSEG
Walmart shares have outperformed the market. Analysts remain overwhelmingly bullish on the stock with more than 80% of analysts rating shares a buy or overweight, according to FactSet. Target shares reflect the strain of the competition. And if Walmart continues to win over wealthier customers, that's more bad news for Target. On Tuesday, KeyBanc Capital Markets analyst Bradley Thomas reiterated that Walmart remains one of his top stock ideas.
Persons: Lindsay Rosner, Piper Sandler, Peter Keith, Keith, Daniel Kurnos, Kurnos, FactSet, Alexis Deladerriere, JLL, Christopher Horvers, JPMorgan's Horvers, Cowen, Oliver Chen, Chen, hasn't, Bradley Thomas, Thomas Organizations: Walmart, Target, Goldman Sachs Asset Management, Analysts, Keith, P Retail, Amazon, Microsoft, Apple, Adobe Analytics, Adobe, Amazon's, Costco, Amazon Prime, Sam's, Paramount, KeyBanc Capital Locations: Wednesday's
But Mizuho expects things will play out differently, and instead raises its price target on the electric vehicle maker, citing challenges with its robotaxis. Morgan Stanley stands by Starbucks, keeping it at an overweight, but lowering its price target. Fong's $155 price target suggests shares can jump another 19.3% over Thursday's closing level, building on a year of monster gains. Analyst Doug Anmuth hiked the mega-cap technology stock's price target by $100 to $750, now implying 14.9% upside from Thursday's close. While he upped his price target by $50 to $197, that fresh target reflects a drop of 18.3%.
Persons: Morgan Stanley, Cody Acree, Acree, — Alex Harring, Jon Tower, Chipotle, Alex Harring, BTIG, Marvin Fong, Fong, Carvana, CarMax, Doug Anmuth, Anmuth, Anmuth's, that's, he's, Christina Cheddar Berk, Vijay Rakesh, Rakesh, Joseph Spak, Spak Organizations: CNBC, UBS, Starbucks, JPMorgan, Netflix, Nvidia, Citi, Harbour, Tesla, robotaxis, Bloomberg Locations: Thursday's, premarket, China
Analysts who have been following companies on the cutting edge of using generative AI for drug discovery say it is still very early days. But these endorsements haven't lifted Recursion shares out of a slump. RXRX 1Y mountain Recursion shares over the past year. The drug company will be a beta user of Recursion's LOWE (Large Language Model-Orchestrated Workflow Engine) and the pair are also partnering on oncology research. SDGR 1Y mountain Schrodinger shares over the past year.
Persons: Scott Schoenhaus, Chris Gibson, Jensen Huang, Leerink, Mani Foroohar, Foroohar, Recursion's, KeyBanc's Schoenhaus, Needham, Gil Blum, it's, Recursion's LOWE, Blum, Eli Lilly, AbCellera, KeyBanc's, Schoenhaus, FactSet, Allison Bratzel, Piper Sandler, Goldman Sachs, Salveen Richter, Peter Lawson, Lawson, Japan's Takeda, Schrodinger, Leerink's Foroohar Organizations: Analysts, Capital, Nvidia, ARK Investment Management, REC, CCM, Union, Bayer, Therapeutics, Dynamo, RLY, Barclays, Japan's Locations: U.S, biopharma, Biohive
The threat from a looming wave of maturing commercial real estate loans has been well telegraphed to investors, but it's possible the metrics they are using to protect themselves from risk are flawed. Many investors have been avoiding bank stocks with high concentrations of commercial real estate (CRE) exposure. Investors have been punishing regional bank stocks, especially when the bank's commercial real estate exposure tops more than 300% of its total equity . While the latter two have some exposure to New York City real estate, both banks benefit from strong management teams, he said. (New York real estate markets are navigating both falling office values as well as the dynamics of rent-regulated multifamily properties.)
Persons: Erika Najarian, Stephens, Matt Breese, Breese, Webster, Najarian, Piper Sandler, Scott Siefers, Siefers, generalists Organizations: Owners, KBW, Regional Banking, UBS, Federal Deposit Insurance Corp, Federal Reserve, Kansas City Fed, NBT Bancorp, Webster, National Bancorp, Micron Technology, Financial Group, Citizens Locations: New York City, York, . Connecticut, New, New York, Providence, R.I
Waste Management , Stericycle — Waste Management is buying Stericycle for $7.2 billion , the companies announced on Monday. Stericycle shares jumped nearly 15%, while Waste Management slid 4%. Spotify — The music streaming company climbed 4% following its announcement of premium subscription price increases in the U.S. in July. Lattice Semiconductor , Coherent — Lattice shares dove 11% after CEO Jim Anderson left to take the helm at Coherent, whose stock price jumped 17%. Krispy Kreme — Shares of the company rose 2% after it was upgraded to overweight at JPMorgan.
Persons: Keith Gill, Gill, Stericycle, CNBC's David Faber, Skydance, Shari Redstone, Jim Anderson, Esam, Dickinson, Edwards, Narendra Modi, Claudia Sheinbaum, Cava, Blackwell, Krispy Kreme, Masimo, Piper, Piper Sandler, Goldman Sachs, Goldman, — CNBC's Sean Colon, Yun Li, Pia Singh, Michelle Fox, Christina Cheddar, Berk Organizations: GameStop, DeepF, AMC, New York Stock Exchange, Waste Management, Spotify, GSK, Court, Paramount Global, Lattice Semiconductor, Company, Bloomberg News, JPMorgan, Nvidia, AMD, Bank of America, Therapeutics, Autodesk Locations: U.S, Swedish, Delaware, Becton, India, Mexico
The cloud security company posted adjusted quarterly earnings of 88 cents per share on revenue of $553 million. MongoDB — MongoDB tumbled 23% after the developer data platform issued second-quarter and full year guidance that was weaker than expected , even as its first-quarter earnings results exceeded expectations. Dell Technologies — The tech stock plunged more than 14% even after Dell beat expectations in its first-quarter results . Otherwise, fiscal first-quarter revenue of $3.34 billion topped the consensus estimate of $3.20 billion. Marvell Technology — The semiconductor stock slid 3% after Marvell Technology missed first-quarter expectations.
Persons: Zscaler, LSEG, MongoDB, Dell, Nordstrom, NetApp, SentinelOne, Michelle, Sun, Choe, , Christina Cheddar, Berk Organizations: Dell Technologies, Dell, LSEG, Costco, Costco Wholesale, Revenue, Marvell Technology, SentinelOne, Corp, VF Corp, Vans
Or, in other cases, it can open the door to new options for the treatment of obstructive sleep apnea. Treating obesity and addressing sleep apnea Sleep apnea is a serious sleep disorder that results in interrupted breathing, preventing patients — and even their sleeping partners — from getting restful and restorative sleep. Obstructive sleep apnea, the most common form, occurs when muscles in the throat relax and collapse preventing air flow. Before qualifying for the device, patients usually need to have tried treatment with a CPAP machine and an oral device and been unsuccessful. He downgraded Inspire shares to hold at the beginning of the year due to this uncertainty he was anticipating.
Persons: Eli Lilly's Zepbound, Anthony Petrone, Medical's, Eli Lilly, Tim Herbert, Zepbound, Herbert, FactSet, Petrone, UnitedHealth, Jonathan Block Organizations: Novo Nordisk's, Mizuho Securities, CNBC, Systems, Inspire, American Diabetes Association, Drug Administration, National Institutes of Health, BMI Locations: U.S
Check out the companies making headlines after the bell : Nvidia — The chipmaker added about 4% after announcing a 10-for-1 stock split . Nvidia also surpassed Wall Street's fiscal first-quarter estimates on the top and bottom lines, and it issued strong guidance for the current quarter. Fiscal first-quarter revenue surpassed the Street's expectations, coming in at $829 million, versus consensus estimates for $786 million, per LSEG. — The apparel and footwear company sank 9% after posting an unexpected loss for the recent quarter and revenue that fell short of Wall Street's estimates. VF Corp. posted a loss of 32 cents per share on $2.37 billion in revenue.
Persons: LSEG, FactSet, Synopsys, LiveRamp, Dow Jones, Goldman Sachs, Morgan Stanley, Ed Breen, Lori Koch, Breen, , Darla Mercado, Sarah Min, Scott Schnipper, Christina Cheddar, Berk Organizations: Nvidia, Super Micro, Devices, Corp, VF Corp, LiveRamp Holdings, News Corp, JPMorgan, DuPont de Nemours, DuPont
The Berkshire Hathaway annual shareholders meeting Saturday will be broadcast exclusively on CNBC and livestreamed on CNBC.com. Chairman and CEO Warren Buffett is expected to field questions from Berkshire Hathaway shareholders who are attending the meeting in Omaha, beginning at 10:15 a.m. The event is always closely watched, but this year's will be noteworthy because Buffett won't have Charlie Munger by his side. Munger, the former vice chairman of Berkshire, was known for his sharp wit, and his absence is being felt by the thousands attending the event. Among the questions that will be top of mind at the "Woodstock or Capitalists" will be what Buffett's mystery holding is.
Persons: Warren Buffett, Berkshire Hathaway, Buffett, Charlie Munger, Munger Organizations: Berkshire Hathaway, CNBC, Berkshire Locations: Omaha, Berkshire, Woodstock
Check out the companies making headlines in after-hours trading: Apple — The iPhone maker advanced 7% as it announced a $110 billion share repurchase and a top- and bottom-line beat. That surpassed analysts' estimates for earnings of $1.50 per share on revenue of $90.01 billion, per LSEG. Expedia posted a beat on first-quarter revenue, which came in at $2.89 billion, surpassing analysts' estimates of $2.81 billion, per LSEG. Block reported adjusted earnings of 85 cents per share on revenue of $5.96 billion in the first quarter. Those results beat analysts' estimates for earnings of 72 cents per share and revenue of $5.82 billion, per LSEG.
Persons: Expedia, Amgen, LSEG, Fortinet, Cloudflare, DaVita, FactSet, , Christina Cheddar, Berk Organizations: Apple Locations: billings
Tirzepatide is the active ingredient in both Eli Lilly's diabetes treatment Mounjaro and its anti-obesity drug Zepbound. Based on that calculation, earnings will be lower by about 13 cents per share, he said, in research published last Tuesday. "Strong demand for Mounjaro & Zepbound can easily pull through in 2H24 and make up for any 1H24 shortfalls." For the week ended April 19, combined prescriptions of Mounjaro and Zepbound rose 63% year over year, according to IQVIA. Wells Fargo Mohit Bansal said he expects investors to look past any Trulicity shortfalls as the focus is firmily on Zepbound and Mounjaro for Lilly's future growth.
Persons: Eli Lilly, Eli, James Shin, Lilly, Shin, David Risinger, Zepbound, Wells, Bansal, Jo Walton, Walton, Lilly's, Tirzepatide, Deutsche Bank's Shin, — CNBC's Michael Bloom Organizations: Drug Administration, Deutsche Bank, IMS, UBS, Research, Deutsche, FDA Locations: 2H24, U.S
Ford Motor — The automobile stock rose 2% after posting a first-quarter adjusted earnings beat and raising its adjusted free cash flow outlook for 2024. On the other hand, Ford's first-quarter revenue came in below expectations. First-quarter revenue of $14.46 billion missed consensus estimates of $14.55 billion, LSEG said. Chipotle earned $13.37 per share, excluding items, outpacing the $11.68 per share LSEG estimate, as traffic to its restaurants was robust. United Rentals — The equipment rental company added 2.4% after posting a first-quarter adjusted earnings and revenue beat.
Persons: LSEG, Ford's, Ethan Allen, Ethan Allen's, Chipotle, Lam, ServiceNow, , Christina Cheddar, Berk, Darla Mercado, Scott Schnipper Organizations: Technology, Facebook, Meta, Ford, Machines, IBM, Whirlpool, Research, Lam Research, Revenue, Churchill, United Rentals
While debate rages on about when the Federal Reserve might start cutting interest rates, biotech industry analysts are making the case that the argument for stocks in the sector is growing. Last week, Morgan Stanley analysts noted that it is the months leading up to an initial rate cut when biotech stocks outperform. Morgan Stanley also believes the case for biotech stocks is further reinforced by the financing environment and the outlook for mergers and acquisitions as well as upcoming innovation. The case for innovation Morgan Stanley also favors owning biotech stocks that have a strong drug platform even if the key catalyst of clinical trial data and FDA approvals are farther out. Rhythm ranks among the stocks rated overweight that Morgan Stanley favors in this category.
Persons: Morgan Stanley, Needham, Joseph Stringer, dealmaking, Stringer, erosive, it's, Phathom, GERD, LSEG, Merck, — CNBC's Michael Bloom Organizations: Federal Reserve, Nasdaq, Oncology, Immunology, Phathom Pharmaceutical, Pharmaceuticals, Phathom Pharmaceuticals, LSEG, Drug, Bristol Myers Squibb, Pfizer, Intellia Therapeutics, Rocket Pharmaceuticals Locations: New Jersey
GE stock has been on a tear, outperforming the market over the past year, as investors bet that the company's break-up will unlock still more value. Since the health-care spinoff, GE shares have risen above $170 from the $60s. He expects anyone buying GE Vernova shares in April will get "a 50% move over the next fourteen months." GE's aerospace business benefits from a dominant market position where it leads in both widebody and narrowbody jet engines. Still, GE Vernova was a weak spot for the company since 2015, according to analysts.
Persons: haven't, FactSet, Gordon Haskett, Don Bilson, GE's, Andrew Obin, Obin, I've, Tony Bancroft, Scott Deuschle, Deuschle, Bancroft, Larry Culp, Culp, GE Vernova, Michael Bloom Organizations: GE Vernova, New York Stock Exchange, GE, GE Healthcare Technologies, General Electric, GE Healthcare, Bank of America, GE Aerospace, Gabelli, Aerospace & Defense ETF, Deutsche Bank, Bank, America's
UiPath — Shares popped 8% after the software company reported fourth-quarter results that beat analysts' expectations. UiPath posted adjusted earnings of 22 cents per share on $405 million in revenue, higher than the 16 cents per share on $384 million in revenue analysts polled by LSEG, formerly Refinitiv, had anticipated. SentinelOne — The cybersecurity name slipped 10% after posting guidance for the first quarter and full year that came in line with analysts' estimates, per LSEG. Robinhood — The trading platform's stock added about 8% after the company reported its selected monthly operating data for February 2024. The company posted a wider-than-expected loss in 2023 and missed its production targets by a considerable margin.
Persons: UiPath, SentinelOne, Armour, Stephanie Linnartz, Kevin Plank, Mohamed El, Robinhood, Fisker, Lennar, LSEG, , Christina Cheddar, Berk, Darla Mercado Organizations: LSEG, Street
In collecting this data, the firm saw a deterioration in the Dollar General brand last year. As of Monday's close, Dollar General's stock is up more than 57% from a 52-week low of $101.09 reached in mid-October. Their research found that consumers felt the cleanliness of Dollar General's stores, a top five driver of satisfaction, lagged key peers Dollar Tree and Family Dollar, and fell 2% further in February. Until November, shoppers rated Family Dollar and Dollar General's product offerings more or less on a par with each other. In addition to Dollar General's own challenges, all dollar stores are likely being hurt by weaker spending among low income consumers.
Persons: Vasos, what's, Todd Vasos, Jeff Owen, Gordon Haskett, Chuck Grom, Grom, bode, Piper Sandler, Peter Keith, Keith, Morgan Stanley, Simeon Gutman, Gutman, Michael Lasser, Lasser, Matthew Boss, — CNBC's Michael Bloom Organizations: Dollar, DG, Occupational Safety, Health Administration, SNAP, UBS, JPMorgan
Total: 25